Abstract：
OBJECTIVE: To acknowledge, the newly available treatments for food allergy described in the latest scientific literature, such as oral immunotherapy (OIT), biologics and the combination of them in managing patients with IgE-mediated food allergies.
RESULTS: Recent studies suggest that OIT and biologics, alone or together, can have a role as disease-modifying treatments for food allergies. The FDA has recently approved omalizumab as a treatment for food allergy. Other biologics are currently under evaluation and further studies are needed to assess the efficacy and safety of these therapies.
CONCLUSIONS: The allergology scenario is rapidly evolving, the recent introduction and approval of new therapeutic strategies such as biotechnological drugs and allergen immunotherapy is changing the therapeutic paradigm: we are witnessing a shift from a strategy based on avoiding the trigger and reversing an allergic reaction already in progress, to one that aims to modify the natural history of the disease by acting on the immunological mechanisms that determine it. This approach is consistent with the modern perspective of a personalized patient-tailored medicine. In this opinion review, we will provide a brief analysis of current and future therapeutic options for IgE-mediated food allergy, focusing on OIT, biologics and their combination.
RESULTS: Recent studies suggest that OIT and biologics, alone or together, can have a role as disease-modifying treatments for food allergies. The FDA has recently approved omalizumab as a treatment for food allergy. Other biologics are currently under evaluation and further studies are needed to assess the efficacy and safety of these therapies.
CONCLUSIONS: The allergology scenario is rapidly evolving, the recent introduction and approval of new therapeutic strategies such as biotechnological drugs and allergen immunotherapy is changing the therapeutic paradigm: we are witnessing a shift from a strategy based on avoiding the trigger and reversing an allergic reaction already in progress, to one that aims to modify the natural history of the disease by acting on the immunological mechanisms that determine it. This approach is consistent with the modern perspective of a personalized patient-tailored medicine. In this opinion review, we will provide a brief analysis of current and future therapeutic options for IgE-mediated food allergy, focusing on OIT, biologics and their combination.
摘要：
目的：确认，最新科学文献中描述的食物过敏的新治疗方法，如口服免疫疗法(OIT)，生物制剂和它们在治疗IgE介导的食物过敏患者中的组合。
结果：最近的研究表明，OIT和生物制剂，单独或一起,可以作为食物过敏的疾病改善治疗。FDA最近批准奥马珠单抗用于治疗食物过敏。其他生物制剂目前正在评估中，需要进一步的研究来评估这些疗法的疗效和安全性。
结论：变态反应学的情况正在迅速演变，最近引入和批准的新的治疗策略，如生物技术药物和过敏原免疫疗法，正在改变治疗模式:我们正在目睹从基于避免触发和逆转已经在进行的过敏反应的策略的转变，旨在通过作用于决定疾病的免疫机制来改变疾病的自然史。这种方法与个性化患者定制医学的现代观点一致。在这次意见审查中，我们将简要分析当前和未来IgE介导的食物过敏的治疗选择，专注于OIT，生物制品及其组合。
结果：最近的研究表明，OIT和生物制剂，单独或一起,可以作为食物过敏的疾病改善治疗。FDA最近批准奥马珠单抗用于治疗食物过敏。其他生物制剂目前正在评估中，需要进一步的研究来评估这些疗法的疗效和安全性。
结论：变态反应学的情况正在迅速演变，最近引入和批准的新的治疗策略，如生物技术药物和过敏原免疫疗法，正在改变治疗模式:我们正在目睹从基于避免触发和逆转已经在进行的过敏反应的策略的转变，旨在通过作用于决定疾病的免疫机制来改变疾病的自然史。这种方法与个性化患者定制医学的现代观点一致。在这次意见审查中，我们将简要分析当前和未来IgE介导的食物过敏的治疗选择，专注于OIT，生物制品及其组合。
